This study is in progress, not accepting new patients
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
Summary
- Eligibility
- for people ages 3-21 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Sabine Mueller, MD, PhD, MASHideho Okada, MD, PhD
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientists at UCSF
- Sabine Mueller, MD, PhD, MAS
Professor, Neurology, School of Medicine - Hideho Okada, MD, PhD
Dr. Okada is a creative physician-scientist who has developed therapeutic modalities in the laboratory, translated them into clinical protocols, and used his expertise as both scientist and clinician to assess the clinical data from ongoing trials. Dr. Okada's work has consistently focused on immunotherapeutic strategies aimed at a daunting challenge in oncology – malignant brain tumors.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Sabine Mueller, MD, PhD
- ID
- NCT02960230
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- About 50 people participating
- Last Updated